

# Geke A P Hospers

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3855020/geke-a-p-hospers-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143  
papers

5,783  
citations

34  
h-index

74  
g-index

155  
ext. papers

7,502  
ext. citations

5.9  
avg, IF

5.36  
L-index

#	Paper	IF	Citations
143	Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , <b>2022</b> , 150, 317-326	7.5	1
142	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	14
141	Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.. <i>BMC Cancer</i> , <b>2022</b> , 22, 247	4.8	0
140	Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study.. <i>European Journal of Cancer</i> , <b>2022</b> , 167, 70-80	7.5	2
139	Clinical Validity of 16[F]Fluoro-17[Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2200400	2.2	1
138	Effect of Extending the Original CROSS Criteria on Tumor Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients: A National Multicenter Cohort Analysis. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 3951-3960	3.1	3
137	Value of screening and follow-up brain MRI scans in patients with metastatic melanoma. <i>Cancer Medicine</i> , <b>2021</b> , 10, 8395-8404	4.8	1
136	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , <b>2021</b> , 31, 58-66	3.3	0
135	Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16[18F]Fluoro-17[Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer. <i>Clinical Nuclear Medicine</i> , <b>2021</b> , 46, e165-e167	1.7	2
134	The unfavorable effects of COVID-19 on Dutch advanced melanoma care. <i>International Journal of Cancer</i> , <b>2021</b> ,	7.5	6
133	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 82-89	2.7	1
132	Interpreting the RAPIDO trial: factors to consider - Authors' reply. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e90-e91.7	11.7	0
131	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 3123-3135	7.4	0
130	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 641-648	8	10
129	Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 5194-5204	3.1	0
128	Value of F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1214-1220	8.9	5
127	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1

126	Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 159, 91-97	5.3	0
125	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 4369-4376 <sup>4</sup>	8.8	4
124	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1995-2004	2.2	42
123	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 29-42	21.7	180
122	Serial [F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 151-161	7.5	4
121	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF-mutant advanced melanoma patients: a propensity-matched survival analysis. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1222-1230	8.7	4
120	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , <b>2021</b> , 15, 510-519	8.8	4
119	OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, iii14-iii14	0.9	78
118	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , <b>2021</b> , 12, 1031-1038	3.6	0
117	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
116	F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	6
115	Adjuvant treatment for melanoma in clinical practice - Trial versus reality. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 234-245	7.5	1
114	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer F-BMS-986192. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1839-1844	8.9	16
113	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
112	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. <i>Cancer and Metastasis Reviews</i> , <b>2020</b> , 39, 999-1013	9.6	18
111	Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. <i>Melanoma Research</i> , <b>2020</b> , 30, 235-246	3.3	17
110	Real-world outcomes of advanced melanoma patients not represented in phase III trials. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3461-3470	7.5	11
109	Application of PET Tracers in Molecular Imaging for Breast Cancer. <i>Current Oncology Reports</i> , <b>2020</b> , 22, 85	6.3	13

108	Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1355-1360	8.9	16
107	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 147, 75-83	5.3	62
106	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
105	Visual and quantitative evaluation of [F]FES and [F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. <i>EJNMMI Research</i> , <b>2020</b> , 10, 40	3.6	5
104	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10002-10002	2.2	36
103	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4006-4006	2.2	67
102	Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10032-10032	2.2	
101	Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. <i>European Journal of Cancer</i> , <b>2020</b> , 126, 11-20	7.5	16
100	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , <b>2020</b> , 30, 261-267	3.3	11
99	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 462-471	2.2	21
98	Image Quality and Interpretation of [F]-FES-PET: Is There any Effect of Food Intake?. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	2
97	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , <b>2020</b> , 5, e000945		2
96	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands - A nationwide population-based study. <i>European Journal of Cancer</i> , <b>2020</b> , 137, 127-135	7.5	7
95	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
94	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. <i>Journal of Immunotherapy</i> , <b>2020</b> , 43, 256-264	5	4
93	Quantitative fluorescence endoscopy: an innovative endoscopy approach to evaluate neoadjuvant treatment response in locally advanced rectal cancer. <i>Gut</i> , <b>2020</b> , 69, 406-410	19.2	15
92	Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 655-661	8.9	16
91	Clinical-grade N-(4-[F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2019</b> , 4, 15	5.8	13

90	Consideration of breast cancer subtype in targeting the androgen receptor. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 200, 135-147	13.9	35
89	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. <i>Oncotarget</i> , <b>2019</b> , 8, 1558664	7.2	
88	Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients. <i>Acta Oncologica</i> , <b>2019</b> , 58, 1640-1647	3.2	5
87	Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry. <i>Cancers</i> , <b>2019</b> , 11,	6.6	16
86	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS9605-TPS9605	23.2	14
85	Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. <i>Journal of Immunotherapy</i> , <b>2019</b> , 42, 208-214	5.1	6
84	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , <b>2019</b> , 11,	6.6	18
83	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 175-185	7.5	7
82	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 579-588	2.4	7
81	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , <b>2018</b> , 29, 572-578	2.4	8
80	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. <i>Melanoma Research</i> , <b>2018</b> , 28, 96-104	3.3	30
79	F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1212-1218	8.9	27
78	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 925-933	7.4	6
77	Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli et al. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1275	4.7	3
76	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 268-275	2.2	60
75	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative F-FDG PET/CT analysis. <i>EJNMMI Research</i> , <b>2018</b> , 8, 101	3.6	18
74	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 877	4.8	66
73	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , <b>2018</b> , 28, 326-332	3.3	5

72	Open-label, multicentre safety study of vemurafenib in 219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 176-184	7.5	23
71	Synthesis and Evaluation of the Estrogen Receptor $\beta$ -selective Radioligand 2-F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with $^{16}\text{F}$ -Fluoro- $^{17}\text{E}$ Estradiol. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 554-559	8.9	16
70	$^{18}\text{F}$ -FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer. <i>Clinical Nuclear Medicine</i> , <b>2017</b> , 42, 612-614	1.7	10
69	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , <b>2017</b> , 72, 156-165	7.5	53
68	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1906-1912	8.9	34
67	In Vivo Quantification of ER $\beta$ Expression by Pharmacokinetic Modeling: Studies with F-FHNP PET. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1743-1748	8.9	5
66	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9524-9524	2.2	14
65	Impact of current insufficient clinical nodal staging on treatment decisions and response to neoadjuvant chemoradiotherapy in esophageal cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 111-111	2.2	
64	Recommendations and Technical Aspects of $^{16}\text{E}$ [ $^{18}\text{F}$ ]Fluoro- $^{17}\text{E}$ Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience. <i>Clinical Nuclear Medicine</i> , <b>2016</b> , 41, 844-851	1.7	28
63	Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients. <i>American Journal of Surgery</i> , <b>2016</b> , 212, 89-95	2.7	0
62	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57 Suppl 1, 96S-104S	8.9	8
61	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11553-11553	2.2	1
60	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9526-9526	2.2	2
59	Multicenter feasibility study of chemoradiation, trastuzumab and pertuzumab in resectable HER2+ esophageal carcinoma: The TRAP study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4142-TPS4142	2.2	
58	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5487-5496	12.9	373
57	Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. <i>Rheumatology</i> , <b>2016</b> , 55, 1143-5	3.9	50
56	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1090-1098	21.7	1266
55	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 634-9	4.9	35



54	CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 117, 152-8	5.3	16
53	Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1674-1681	8.8	32
52	Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16E18F-fluoro-17Eestradiol PET/CT. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 50-5	8.9	34
51	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e133-4	2.2	7
50	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 527-527	2.2	2
49	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 2276-83	3.3	10
48	Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 605-11	3.1	37
47	Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 412	8.3	32
46	Off-label prescription of genetically modified organism medicines in europe: emerging conflicts of interest?. <i>Human Gene Therapy</i> , <b>2014</b> , 25, 893-6	4.8	
45	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 449-58	7.4	207
44	Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 845-52	4	21
43	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 436-44	21.7	206
42	Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 112, 284-8	5.3	35
41	Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 113, 188-92	5.3	17
40	Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. <i>Annals of Surgery</i> , <b>2014</b> , 260, 786-92; discussion 792-3	7.8	97
39	Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. <i>American Journal of Surgery</i> , <b>2014</b> , 208, 215-21	2.7	21
38	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. <i>BMC Cancer</i> , <b>2013</b> , 13, 279	4.8	203
37	Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 4008-15	3.1	35

36	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e465-475	134
35	Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3850-5	7.5 12
34	Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta Oncologica</i> , <b>2013</b> , 52, 1786-8	3.2 60
33	Effect of vemurafenib on a V600R melanoma brain metastasis. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1795-6	7.5 6
32	Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. <i>Annals of Surgical Oncology</i> , <b>2013</b> , 20, 1985-92	3.1 22
31	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , <b>2013</b> , 717, 2-11	5.3 11
30	Towards sustained silencing of HER2/neu in cancer by epigenetic editing. <i>Molecular Cancer Research</i> , <b>2013</b> , 11, 1029-39	6.6 64
29	Abstract 4768: Frequency and prognostic value of hormone receptor expression in epithelial ovarian cancer. <b>2013</b> ,	2
28	Preoperative chemoradiotherapy (CRT) in gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 89-89	2.2
27	PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 182-90	8.9 105
26	Disparities in survival of stomach cancer among different socioeconomic groups in North-East Netherlands. <i>Cancer Epidemiology</i> , <b>2011</b> , 35, 413-6	2.8 16
25	VEGF-SPECT with $^{125}$ I-bevacizumab in stage III/IV melanoma patients. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 1595-602	7.5 46
24	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. <i>Critical Reviews in Oncology/Hematology</i> , <b>2011</b> , 80, 264-77	7 8
23	Retrospective denial as a coping method. <i>Journal of Clinical Psychology in Medical Settings</i> , <b>2011</b> , 18, 65-9	4
22	Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. <i>Oncologist</i> , <b>2011</b> , 16, 783-7	5.7 54
21	VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. <i>Cancer Research</i> , <b>2011</b> , 71, 143-53	10.1 94
20	Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. <i>Methods in Molecular Biology</i> , <b>2010</b> , 596, 15-31	1.4 11
19	A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. <i>Journal of Medical Case Reports</i> , <b>2010</b> , 4, 10	1.2 5



18	Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. <i>Gastric Cancer</i> , <b>2010</b> , 13, 95-100	7.6	0
17	Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen. <i>Vaccine</i> , <b>2009</b> , 28, 386-91	4.1	1
16	<sup>18</sup> F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. <i>Oncologist</i> , <b>2008</b> , 13, 734-5; author reply 736-7	5.7	16
15	Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound. <i>Drug Delivery</i> , <b>2007</b> , 14, 273-7	7	17
14	Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response. <i>Acute Cardiac Care</i> , <b>2006</b> , 8, 41-5		9
13	A review on pro- and anti-angiogenic factors as targets of clinical intervention. <i>Pharmacological Research</i> , <b>2006</b> , 53, 89-103	10.2	126
12	<sup>18</sup> F-FEAU as a radiotracer for herpes simplex virus thymidine kinase gene expression: in-vitro comparison with other PET tracers. <i>Nuclear Medicine Communications</i> , <b>2006</b> , 27, 25-30	1.6	47
11	Functional characteristics of coronary vasomotor function following intramyocardial gene therapy with naked DNA encoding for vascular endothelial growth factor165. <i>Endothelium: Journal of Endothelial Cell Research</i> , <b>2005</b> , 12, 103-6		5
10	Influence of p53 status on the HSV-Tk/GCV-induced bystander effect in a panel of human ovarian carcinoma cell lines. <i>Oncology Research</i> , <b>2005</b> , 15, 151-9	4.8	3
9	Treatment of locally advanced rectal cancer. <i>Surgical Oncology</i> , <b>2004</b> , 13, 137-47	2.5	13
8	PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. <i>Journal of Nuclear Medicine</i> , <b>2004</b> , 45, 1437-43	8.9	27
7	combination of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) to improve angiogenic gene therapy. <i>Angiogenesis</i> , <b>2003</b> , 6, 185-92	10.6	5
6	Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. <i>Angiogenesis</i> , <b>2003</b> , 6, 283-7	10.6	359
5	Evaluation of [ <sup>18</sup> F]FHPG as PET tracer for HSVtk gene expression. <i>Nuclear Medicine and Biology</i> , <b>2003</b> , 30, 651-60	2.1	16
4	Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. <i>Current Gene Therapy</i> , <b>2002</b> , 2, 307-22	4.3	115
3	Scintigraphic imaging of HSVtk gene therapy. <i>Current Pharmaceutical Design</i> , <b>2002</b> , 8, 1435-50	3.3	18
2	Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. <i>Angiogenesis</i> , <b>2001</b> , 4, 91-102	10.6	257
1	[( <sup>11</sup> C)FMAU and [( <sup>18</sup> F)FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. <i>Nuclear Medicine and Biology</i> , <b>2000</b> , 27, 113-9	2.1	62

